5-Amino-1MQ vs MOTS-C: two NAD+ levers, very different evidence

5-amino-1MQ and MOTS-C get lumped together as "NAD+ fat-loss compounds," and both do raise NAD+ and activate SIRT1. But the way they get there could not be more different, and so is the evidence behind them.

5-amino-1MQ is a small oral molecule (not a peptide) that inhibits NNMT, an enzyme overexpressed in white fat tissue. Blocking NNMT stops nicotinamide being wasted, so NAD+ rises inside the fat cell, SIRT1 switches on, and adipocytes shift toward burning energy. The catch: every efficacy study is in mice. There are no completed human trials and oral bioavailability in people has never been measured.

MOTS-C is a 16-amino-acid mitochondrial-derived peptide. It activates AMPK (the same pathway exercise and metformin recruit), primarily in skeletal muscle, driving glucose uptake and fat oxidation. NAD+ elevation is downstream. Its evidence is thin too, but slightly less thin than 5-amino-1MQ: mouse efficacy plus human observational data and one exercise RCT.

The practical split: 5-amino-1MQ is the oral, fat-tissue lever; MOTS-C is the injectable, muscle lever. They are not redundant, which is exactly why some people stack them.

Mechanism and target organ: 5-amino-1MQ inhibits the NNMT enzyme in adipose tissue and liver, raising NAD+ directly. MOTS-C activates AMPK in skeletal muscle, with NAD+ elevation as a secondary effect. Different entry points, different primary organs.

Evidence quality: This is the real difference. 5-amino-1MQ is preclinical only, with zero completed human trials. MOTS-C has mouse efficacy plus human observational correlations and an exercise RCT. Neither has a completed fat-loss intervention trial in humans, so both are speculative, but MOTS-C is marginally further along.

Route: 5-amino-1MQ is oral, its single biggest practical advantage. MOTS-C is a subcutaneous injection.

Appetite and anabolism: Neither suppresses appetite or builds muscle directly. Both are metabolic tools, not anabolics.

What the animal data shows: 5-amino-1MQ reduced fat mass without changing food intake in diet-induced obese mice (Neelakantan et al., 2018). MOTS-C prevented diet-induced obesity and reversed insulin resistance in mice (Lee et al., 2015). Both are mouse results.

Bloodwork signal: both target insulin sensitivity, so HOMA-IR is the readout for either. 5-amino-1MQ also lowered triglycerides and liver fat in mice; MOTS-C correlates with HOMA-IR improvement in human observational data.

Doping status: both are WADA-prohibited. MOTS-C is explicitly named as an AMPK activator (S4.4.1); 5-amino-1MQ falls under prohibited metabolic modulators and non-approved substances.

Choose 5-amino-1MQ if:

• You want an oral option and will not inject
• You are targeting stubborn fat with an adipocyte-level mechanism
• You accept it is the least-proven of the two, with no human data at all, and you will track HOMA-IR and lipids to see if it does anything for you

Choose MOTS-C if:

• You are comfortable with subcutaneous injections
• Your interest is muscle insulin sensitivity and glucose partitioning, especially as an older athlete with declining endogenous MOTS-C
• You want the (slightly) better-supported of the two

On stacking them:

• The pairing has a clean theoretical logic: MOTS-C increases NAD+ demand via AMPK, while 5-amino-1MQ protects the NAD+ pool by blocking its drain. Different organs, non-overlapping mechanisms.
• But there is zero human data on the combination. Treat it as an experiment, hold other variables constant, and let HOMA-IR and bodyfat trends over 8 to 12 weeks tell you whether it is worth the money.
• If your actual goal is proven fat loss, neither of these is the answer. Retatrutide has the human trial data; these are NAD+ optimization bets layered on top.